Inhibition of c-src transcription by mithramycin: Structure-activity relationships of biosynthetically produced mithramycin analogues using the c-src promoter as target

Biochemistry

Volumn 42, Issue 27, 2003, Pages 8313-8324

  Remsing, Lily L ^a   Bahadori, Hamid R ^b   Carbone, Giuseppina M ^b   McGuffie, Eileen M ^b   Catapano, Carlo V ^b   Rohr, Jürgen ^a  

^a University of Kentucky   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTICS; BIOSYNTHESIS; BONE; DNA; GROWTH KINETICS;

TRANSCRIPTION FACTORS;

TUMORS;

4C KETODEMYCAROSYLMITHRAMYCIN; 4E KETOMITHRAMYCIN; 7 NORMITHRAMYCIN; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; MITHRAMYCIN; MITHRAMYCIN SK; PREMITHRAMYCIN B; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BIOSYNTHESIS; CANCER CELL; CONTROLLED STUDY; DNA BINDING; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; ONCOGENE SRC; PRIORITY JOURNAL; PROMOTER REGION; REPORTER GENE; STRUCTURE ACTIVITY RELATION;

ANTIBIOTICS, ANTINEOPLASTIC; BASE SEQUENCE; DNA; DNA PRIMERS; GENES, SRC; HUMANS; MOLECULAR SEQUENCE DATA; PLICAMYCIN; PROMOTER REGIONS (GENETICS); STRUCTURE-ACTIVITY RELATIONSHIP; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 0038164676     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi034091z     Document Type: Article

References (69)

1. Jayasuriya, H., Lingham, R. B., Graham, P., Quamina, D., Herranz, L., Genilloud, O., Gagliardi, M., Danzeisen, R., Tomassini, J. E., Zink, D. L., Guan, Z. Q., and Singh, S. B. (2002) Durhamycim A, a potent inhibitor of HIV Tat transactivation, J. Nat. Prod. 65, 1091-1095.
2. Krishna, N. R., Miller, D. M., and Sakai, T. T. (1990) NMR and fluorometric characterization of mithramycin in aqueous solution, J. Antibiot. 43, 1543-1552.
3. Gause, G. F. (1975) Olivomycin, chromomycin, and mithramycin, in Antibiotics III. Mechanism of action of antimicrobial antitumor agents (Corcoran, J. W., and Hahn, F. E., Eds.) pp 197-202, Springer-Verlag, Berlin and New York.
4. 3, mithramycin A, and olivomycin A, in Antitumor compounds of natural origin: Chemistry and biochemistry (Aszalos, A., Ed.) pp 191-235, CRC Press, Boca Raton, FL.
5. Fox, K. R., and Howarth, N. R. (1985) Investigations into the sequence-selective binding of mithramycin and related ligands to DNA, Nucleic Acids Res. 13, 8695-8714.
6. Sastry, M., and Patel, D. J. (1993) Solution structure of the mithramycin dimer-DNA complex, Biochemistry 32, 6588-6604.
7. Sastry, M., Fiala, R., and Patel, D. J. (1995) Solution structure of mithramycin dimers bound to partially overlapping sites on DNA, J. Mol. Biol. 251, 674-689.
8. Majee, S., Dasgupta, D., and Chakrabarti, A. (1999) Interaction of the DNA-binding antitumor antibiotics chromomycin and mithramycin with erythroid spectrin, Eur. J. Biochem. 260, 619-626.
9. Elias, E. G., and Evans, J. T. (1972) Mithramycin in the treatment of Paget's disease of bone, J. Bone Joint Surg. 54-A, 1730-1736.
10. Brown, J. H., and Kennedy, B. J. (1965) Mithramycin in the treatment of disseminated testicular neoplasms, N. Engl. J. Med. 272, 111-118.
11. Ryan, W. G., Schwartz, T. B., and Northrop, G. (1970) Experiences in the treatment of Paget's disease of bone with mithramycin, J. Am. Med. Assoc. 213, 1153-1157.
12. Robins, P. R., and Jowsey, J. (1973) Effect of mithramycin on normal and abnormal bone turnover, J. Lab. Clin. Med. 82, 576-586.
13. Dewick, P. M. (1997) Medicinal natural products: A biosynthetic approach, p 85, Wiley, Chichester, NY.
14. 2+ complexes with DNA, Biochemistry, 34, 1376-1385.
15. Majee, S., and Chakrabarti, A. (1999) Membrane interaction of an antitumor antibiotic, mithramycin, with anionic phospholipid vesicles, Biochem. Pharmacol. 57, 981-987.
16. Suske, G. (1999) The Sp-family of transcription factors, Gene 238, 291-300.
17. 3 are potent inhibitors of neuronal apoptosis induced by oxidative stress and DNA damage in cortical neurons, Ann. Neurol. 49, 345-354.
18. Nehls, M. C., Brenner, D. A., Gruss, H. J., Dierbach, H., Mertelsmann, R., and Herrmann, F. (1993) Mithramycin selectively inhibits collagen-alpha 1(I) gene expression in human fibroblast, J. Clin. Invest. 92, 2916-2921.
19. Blume, S. W., Snyder, R. C., Ray, R., Thomas, S., Koller, C. A., and Miller, D. M. (1991) Mithramycin inhibits Spl binding and selectively inhibits transcriptional activity of the dihydrofolate reductase gene in vitro and in vivo, J. Clin. Invest. 88, 1613-1621.
20. Snyder, R. C., Ray, R., Blume, S., and Miller, D. M. (1991) Mithramycin blocks transcriptional initiation of the c-myc P1 and P2 promoters, Biochemistry 30, 4290-4297.
21. Ray, R., Snyder, R. C., Thomas, S., Koller, C. A., and Miller, D. M. (1989) Mithramycin blocks protein binding and function of the SV40 early promoter, J. Clin. Invest. 83, 2003-2007.
22. Ritchie, S., Boyd, F. M., Wong, J., and Bonham, K. (2000) Transcription of the human c-Src promoter is dependent on Sp1, a novel pyrimidine binding factor SPy, and can be inhibited by triplex-forming oligonucleotides, J. Biol. Chem. 275, 847-854.
23. Irby, R. B., and Yeatman, T. J. (2000) Role of Src expression and activation in human cancer, Oncogene 19, 5636-5642.
24. Biscardi, J. S., Tice, D. A., and Parsons, S. J. (1999) c-Src, receptor tyrosine kinases, and human cancer, Adv. Cancer Res. 76, 61-119.
25. Soriano, P., Montgomery, C., Geske, R., and Bradley, A. (1991) Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice, Cell 64, 693-702.
26. Hall, T. J., Schaeublin, M., and Chambers, T. J. (1993) The majority of osteoclasts require mRNA and protein synthesis for bone resorption in vitro, Biochem. Biophys. Res. Commun. 195, 1245-1253.
27. Calabresi, P., and Chabner, B. A. (1991) Antineoplastic agents, in The pharmacological basis of therapeutics (Goodman-Gilman, A., Ed.) pp 1209-1263, Pergamon Press, Oxford, U.K.
28. Gonzalez, A., Remsing, L. L., Lombo, F., Fernandez, M. J., Prado, L., Brana, A. F., Kunzel, E., Rohr, J., Mendez, C., and Salas, J. A. (2001) The mtmVUC genes of the mithramycin gene cluster in Streptomyces argillaceus are involved in the biosynthesis of the sugar moieties, Mol. Gen. Genet. 264, 827-835.
29. Lozano, M. J. F., Remsing, L. L., Quiros, L. M., Brana, A. F., Fernandez, E., Sanchez, C., Mendez, C., Rohr, J., and Salas, J. A. (2000) Characterization of two polyketide methyltransferases involved in the biosynthesis of the antitumor drug mithramycin by Streptomyces argillaceus, J. Biol. Chem. 275, 3065-3074.
30. Remsing, L. L., Garcia-Bernardo, J., Gonzalez, A., Kunzel, E., Rix, U., Brana, A. F., Bearden, D. W., Mendez, C., Salas, J. A., and Rohr, J. (2002) Ketopremithramycins and ketomithramycins, four new aureolic acid-type compounds obtained upon inactivation of two genes involved in the biosynthesis of the deoxysugar moieties of the antitumor drug mithramycin by Streptomyces argillaceus, reveal novel insights into post-PKS tailoring steps of the mithramycin biosynthetic pathway, J. Am. Chem. Soc. 124, 1606-1614.
31. Remsing, L. L., Gonzalez, A. M., Nur-e-Alam, M., Fernandez-Lonzano, M. J., Brana, A. F., Rix, U., Oliveira, M. A., Mendez, C., Salas, J. A., and Rohr, J. (2003) Mithramycin SK, a novel antitumor drug with improved therapeutic index, mithramycin SA, and demycarosyl-mithramycin SK: Three new products generated in the mithramycin producer Streptomyces argillaceus through combinatorial biosynthesis, J. Am. Chem. Soc. 125, 5745-5753.
32. Prado, L., Fernandez, E., Weissbach, U., Blanco, G., Quiros, L. M., Brana, A. F., Mendez, C., Rohr, J., and Salas, J. A. (1999) Oxidative cleavage of premithramycin B is one of the last steps in the biosynthesis of the antitumor drug mithramycin, Chem. Biol. 6, 19-30.
33. Carpenter, M. L., Marks, J. N., and Fox, K. R. (1993) DNA-sequence binding preference of the GC-selective ligand mithramycin. Deoxyribonuclease-I/deoxyribonuclease-II and hydroxyradical footprinting at CCCG, CCGC, CGGC, GCCC and GGGG flanked by (AT)n and An.Tn, Eur. J. Biochem. 215, 561-566.
34. Chen, G., Wang, G. Y., Li, X., Waters, B., and Davies, J. (2000) Enhanced production of microbial metabolites in the presence of dimethyl sulfoxide, J. Antibiot. 53, 1145-1153.
35. Cons, B. M., and Fox, K. R. (1990) The GC-selective ligand mithramycin alters the structure of (AT)n sequences flanking its binding sites, FEBS Lett. 264, 100-104.
36. Cons, B. M., and Fox, K. R. (1990) Footprinting studies of sequence recognition by mithramycin, Anti-Cancer Drug Des. 5, 93-97.
37. Cons, B. M., and Fox, K. R. (1991) Effects of the antitumor antibiotic mithramycin on the structure of repetitive DNA regions adjacent to its GC-rich binding site, Biochemistry 30, 6314-6321.
38. Bonham, K., and Fujita, D. J. (1993) Organization and analysis of the promoter region and 5′ noncoding exons of the human c-src proto-oncogene, Oncogene 8, 1973-1981.
39. McGuffie, E. M., and Catapano, C. V. (2002) Design of a novel triple helix-forming oligodeoxyribonucleotide directed to the major promoter of the c-myc gene, Nucleic Acids Res. 30, 2701-2709.
40. Kilwinski, J., Baack, M., Heiland, S., and Knippers, R. (1995) Transcription factor Oct1 binds to the AT-rich segment of the Simian virus 40 replication origin, J. Virol. 69, 575-578.
41. Catapano, C. V., McGuffie, E. M., Pacheco, D., and Carbone, G. M. (2000) Inhibition of gene expression and cell proliferation by triple helix-forming oligonucleotides directed to the c-myc gene, Biochemistry 39, 5126-5138.
42. Furstoss, O., Dorey, K., Simon, V., Barila, D., Superti-Furga, G., and Roche, S. (2002) c-Ab1 is an effector of Src for growth factor-induced c-myc expression and DNA synthesis, EMBO J. 21, 514-524.
43. Bjorge, J. D., Jakymiw, A., and Fujita, D. J. (2000) Selected glimpses into the activation and function of Src kinase, Oncogene 19, 5620-5635.
44. Irby, R. B., Mao, W., Coppola, D., Kang, J., Loubeau, J. M., Trudeau, W., Karl, R., Fujita, D. J., Jove, R., and Yeatman, T. J. (1999) Activating SRC mutation in a subset of advanced human colon cancers, Nat. Genet. 21, 187-190.
45. Hall, T. J., Schaeublin, M., and Missbach, M. (1994) Evidence that c-src is involved in the process of osteoclastic bone resorption, Biochem. Biophys. Res. Commun. 199, 1237-1244.
46. Mundy, G. R. (1993) Cytokines and growth factors in the regulation of bone remodeling, J. Bone Miner. Res. 8, S505-S510.
47. Yoneda, T., Lowe, C., Lee, C. H., Gutierrez, G., Niewolna, M., Williams, P. J., Izbicka, E., Uehara, Y., and Mundy, G. R. (1993) Herbimycin A, a pp60c-Src tyrosine kinase inhibitor, inhibits osteoclastic bone resorption in vitro and hypercalcemia in vivo, J. Clin. Invest. 91, 2791-2795.
48. Kami, R., Jove, R., and Levitzki, A. (1999) Inhibition of pp60c-Src reduces Bcl-XL expression and reverses the transformed phenotype of cells overexpressing EGF and HER-2 receptors, Oncogene 18, 4654-4662.
49. Rabow, A. A., Shoemaker, R. H., Sausville, E. A., and Covell, D. G. (2002) Mining the National Cancer Institute's tumor-screening database: Identification of compounds with similar cellular activities, J. Med. Chem. 45, 818-840.
50. 2+ complex in methanol: Role of the carbohydrates in complex formation, J. Am. Chem. Soc. 115, 7962-7970.
51. 3 stabilize the Mg(2+)-dimer complex, Biochemistry, 32, 463-471.
52. Gao, X. L., Mirau, P., and Patel, D. J. (1992) Structure refinement of the chromomycin dimer-DNA oligomer complex in solution, J. Mol. Biol. 223, 259-279.
53. 2+ coordination, Biochimie 77, 729-738.
54. Boyd, M. R. (1989) Status of the NCI preclinical antitumor drug discovery screen, Princ. Pract. Oncol. 3, 1-12.
55. Boyd, M. R. (1995) Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen, Drug Dev. Res. 34, 91-109.
56. Boyd, M. R. (1997) The NCI in vitro anticancer drug discovery screen. Concept, implementation, and operation, 1985-1995, in Anticancer drug development guide: Preclinical screening, clinical trials, and approval (Teicher, B., Ed.) pp 23-42, Humana Press, Totowa, NJ.
57. Monks, A., Scudiero, D., Skehan, P., Shoemaker, R., Paull, K., Vistica, D., Hose, C., Langley, J., Cronise, P., and Vaigro-Wolff, A. (1991) Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines, J. Natl. Cancer Inst. 83, 757-766.
58. Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenney, S., and Boyd, M. R. (1990) New colorimetric cytotoxicity assay for anticancer-drug screening, J. Natl. Cancer Inst. 82, 1107-1112.
59. 2 as determined by NMR, Nucleic Acids Res. 26, 744-755.
60. Ogawa, H., Yamashita, Y., Katahira, R., Chiba, S., Iwasaki, T., Ashizawa, T., and Nakano, H. (1998) UCH9, a new antitumor antibiotic produced by Streptomyces: I. Producing organism, fermentation, isolation and biological activities, J. Antibiot. 51, 261-266.
61. 3, Biochemistry 29, 9294-9304.
62. Keniry, M. A., Owen, E. A., and Shafer, R. H. (2000) The three-dimensional structure of the 4:1 mithramycin:d(ACCCGGGT)-(2) complex: evidence for an interaction between the E saccharides, Biopolymers 54, 104-114.
63. 2. Evidence that the saccharide chains have a role in sequence specificity, J. Mol. Biol. 231, 753-767.
64. 2: Role of sugars in antibiotic-DNA recognition, J. Phys. Chem. 106, 6947-6953.
65. Chakrabarti, S., Bhattacharyya, D., and Dasgupta, D. (2001) Structural basis of DNA recognition by anticancer antibiotics, chromomycin A(3), and mithramycin: Roles of minor groove width and ligand flexibility, Biopolymers 56, 85-95.
66. Behr, W., Honikel, K., and Hartmann, G. (1969) Interaction of the RNA polymerase inhibitor chromomycin with DNA, Eur. J. Biochem. 9, 82-92.
67. Fox, K. R., and Waring, M. J. (1984) DNA structural variations produced by actinomycin and distamycin as revealed by DNAase I footprinting, Nucleic Acids Res. 12, 9271-9285.
68. Drew, H. R., and Travers, A. A. (1984) DNA structural variations in the E. coli tyrT promoter, Cell 37, 491-502.
69. Bonham, K., Ritchie, S. A., Dehm, S. M., Snyder, K., and Boyd, F. M. (2000) An alternative, human SRC promoter and its regulation by hepatic nuclear factor-1alpha, J. Biol. Chem. 275, 37604-37611.